vs
Apellis Pharmaceuticals, Inc.（APLS）与Cricut, Inc.（CRCT）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Cricut, Inc.的1.3倍（$199.9M vs $159.5M），Cricut, Inc.净利率更高（12.7% vs -29.5%，领先42.2%），Cricut, Inc.同比增速更快（-1.9% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -2.6%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Cricut, Inc.是面向家庭手工爱好者的美国品牌，主营计算机控制的切割机产品。这类设备可切割纸张、毛毡、乙烯基、布料，也可加工皮革、纸板、木材等多种材料，是手工创作场景的实用工具。
APLS vs CRCT — 直观对比
营收规模更大
APLS
是对方的1.3倍
$159.5M
营收增速更快
CRCT
高出4.0%
-5.9%
净利率更高
CRCT
高出42.2%
-29.5%
两年增速更快
APLS
近两年复合增速
-2.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $159.5M |
| 净利润 | $-59.0M | $20.3M |
| 毛利率 | — | 58.1% |
| 营业利润率 | -25.6% | 14.4% |
| 净利率 | -29.5% | 12.7% |
| 营收同比 | -5.9% | -1.9% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCRCT
| Q1 26 | — | $159.5M | ||
| Q4 25 | $199.9M | $203.6M | ||
| Q3 25 | $458.6M | $170.4M | ||
| Q2 25 | $178.5M | $172.1M | ||
| Q1 25 | $166.8M | $162.6M | ||
| Q4 24 | $212.5M | $209.3M | ||
| Q3 24 | $196.8M | $167.9M | ||
| Q2 24 | $199.7M | $167.9M |
净利润APLSCRCT
| Q1 26 | — | $20.3M | ||
| Q4 25 | $-59.0M | $7.8M | ||
| Q3 25 | $215.7M | $20.5M | ||
| Q2 25 | $-42.2M | $24.5M | ||
| Q1 25 | $-92.2M | $23.9M | ||
| Q4 24 | $-36.4M | $11.9M | ||
| Q3 24 | $-57.4M | $11.5M | ||
| Q2 24 | $-37.7M | $19.8M |
毛利率APLSCRCT
| Q1 26 | — | 58.1% | ||
| Q4 25 | — | 47.4% | ||
| Q3 25 | — | 55.2% | ||
| Q2 25 | — | 59.0% | ||
| Q1 25 | — | 60.5% | ||
| Q4 24 | — | 44.9% | ||
| Q3 24 | — | 46.1% | ||
| Q2 24 | — | 53.5% |
营业利润率APLSCRCT
| Q1 26 | — | 14.4% | ||
| Q4 25 | -25.6% | 6.8% | ||
| Q3 25 | 48.7% | 13.3% | ||
| Q2 25 | -18.6% | 17.5% | ||
| Q1 25 | -50.0% | 18.0% | ||
| Q4 24 | -12.3% | 6.6% | ||
| Q3 24 | -24.0% | 6.3% | ||
| Q2 24 | -14.7% | 15.7% |
净利率APLSCRCT
| Q1 26 | — | 12.7% | ||
| Q4 25 | -29.5% | 3.8% | ||
| Q3 25 | 47.0% | 12.0% | ||
| Q2 25 | -23.6% | 14.2% | ||
| Q1 25 | -55.3% | 14.7% | ||
| Q4 24 | -17.1% | 5.7% | ||
| Q3 24 | -29.2% | 6.8% | ||
| Q2 24 | -18.9% | 11.8% |
每股收益（稀释后）APLSCRCT
| Q1 26 | — | $0.10 | ||
| Q4 25 | $-0.40 | $0.03 | ||
| Q3 25 | $1.67 | $0.10 | ||
| Q2 25 | $-0.33 | $0.11 | ||
| Q1 25 | $-0.74 | $0.11 | ||
| Q4 24 | $-0.30 | $0.06 | ||
| Q3 24 | $-0.46 | $0.05 | ||
| Q2 24 | $-0.30 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $236.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $357.5M |
| 总资产 | $1.1B | $543.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSCRCT
| Q1 26 | — | $236.5M | ||
| Q4 25 | $466.2M | $275.6M | ||
| Q3 25 | $479.2M | $207.1M | ||
| Q2 25 | $370.0M | $376.9M | ||
| Q1 25 | $358.4M | $356.7M | ||
| Q4 24 | $411.3M | $336.9M | ||
| Q3 24 | $396.9M | $246.9M | ||
| Q2 24 | $360.1M | $299.5M |
股东权益APLSCRCT
| Q1 26 | — | $357.5M | ||
| Q4 25 | $370.1M | $343.6M | ||
| Q3 25 | $401.2M | $358.4M | ||
| Q2 25 | $156.3M | $308.9M | ||
| Q1 25 | $164.2M | $490.2M | ||
| Q4 24 | $228.5M | $466.8M | ||
| Q3 24 | $237.1M | $475.8M | ||
| Q2 24 | $264.3M | $448.5M |
总资产APLSCRCT
| Q1 26 | — | $543.8M | ||
| Q4 25 | $1.1B | $580.8M | ||
| Q3 25 | $1.1B | $564.3M | ||
| Q2 25 | $821.4M | $721.5M | ||
| Q1 25 | $807.3M | $681.7M | ||
| Q4 24 | $885.1M | $693.0M | ||
| Q3 24 | $901.9M | $663.8M | ||
| Q2 24 | $904.5M | $742.1M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSCRCT
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $82.4M | ||
| Q3 25 | $108.5M | $20.5M | ||
| Q2 25 | $4.4M | $36.2M | ||
| Q1 25 | $-53.4M | $61.2M | ||
| Q4 24 | $19.4M | $103.1M | ||
| Q3 24 | $34.1M | $70.2M | ||
| Q2 24 | $-8.3M | $35.0M |
自由现金流APLSCRCT
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — |
自由现金流率APLSCRCT
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — |
资本支出强度APLSCRCT
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — |
现金转化率APLSCRCT
| Q1 26 | — | — | ||
| Q4 25 | — | 10.58× | ||
| Q3 25 | 0.50× | 1.00× | ||
| Q2 25 | — | 1.48× | ||
| Q1 25 | — | 2.56× | ||
| Q4 24 | — | 8.64× | ||
| Q3 24 | — | 6.11× | ||
| Q2 24 | — | 1.77× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CRCT
| Platform | $84.8M | 53% |
| Products | $74.7M | 47% |
